ESRT Putting 1359 Broadway Up for Sale, Seeking $225M

Empire State Realty Trust (ESRT) is marketing its mixed-use property at 1359 Broadway for sale, seeking about $225 million, according to sources cited by Commercial Observer. The 486,000 sq ft, 22-story office and retail building is about 95% leased. Recent leases include Infinium Wall Systems and ESRT deals in Q2 2025. No debt encumbers the property.

Original reporting
Published Jul 23, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ESRT Putting 1359 Broadway Up for Sale, Seeking $225M — source image
Decision brief

The 30-second read

$ESRTNeutralMed
01

Why it matters

If the sale closes near the targeted $225M, ESRT could improve liquidity and potentially reduce leverage or fund redeployment, while the property’s ~95% leased status and recent tenant signings support near-term cash flow quality.

02

Market read

A targeted $225M sale of a highly leased Midtown mixed-use asset is a concrete portfolio-catalyst for ESRT, but traders will need confirmation of definitive terms and closing timeline.

03

What to watch

The article does not state expected closing date, transaction structure (e.g., any contingencies), or how proceeds will be deployed (deleveraging vs reinvestment), which are key drivers of ESRT’s near-term valuation impact.

Relevance 7/10Novelty 7/10Timing: as ESRT markets 1359 Broadway for sale, ahead of potential buyer selection and closing updates

Background

ESRT is actively reshaping its portfolio, including recent acquisitions and sales of Midtown Manhattan office assets, and this new listing is framed as additional capital recycling.

Company-level read

Ticker impact

$ESRTNeutralMedium confidence
Context

Empire State Realty Trust is marketing 1359 Broadway for sale, targeting about $225M, with ~95% leased occupancy and no encumbering debt.

Expected impact

Likely modest positive bias if investors view proceeds as deleveraging and reinvestment capacity, but magnitude depends on buyer/terms and any resulting guidance changes.

Evidence & confidence

The article provides deal size ($225M), occupancy/leasing momentum (~95% leased, recent leases), and notes no debt encumbers the property, but it does not disclose definitive contract terms, expected closing date, or how proceeds will be used.

Market effects

Signals continued office-asset recycling by a REIT, which can influence sector read-through on liquidity for well-leased, transit-adjacent properties.

Highlights demand for Midtown Manhattan office/retail assets near Penn Station and Grand Central, potentially supporting pricing expectations for similar buildings.

Limited direct global impact; primarily affects US REIT capital allocation and office real-estate transaction sentiment.

Counterpoint

The headline price target may not translate into a completed sale; if leasing momentum slows or cap-rate expectations move, proceeds could come in below $225M and pressure sentiment.

Key entities

  • Empire State Realty Trust

    REIT marketing 1359 Broadway for sale, targeting about $225M and citing ~95% leased occupancy and leasing momentum.

  • Newmark

    Newmark team members are leading the sale effort for the property.

  • Infinium Wall Systems

    Signed a lease for 30,017 square feet at 1359 Broadway (recently cited).

  • SLCE Architects

    ESRT signed 38,000 square feet of leases between SLCE Architects and nonprofit Braven in Q2 2025 (as cited).

  • Wolfgang’s Steakhouse

    Anchors the retail component of 1359 Broadway.

Related articles

$ESRTMed

Declining Empire State Building Visits Drive Q2 Loss for ESRT

New York City’s declines in international tourism over the past year since President Donald Trump assumed office are starting to affect Empire State Realty Trust (ESRT)’s finances. The real estate investment trust (REIT) reported second-quarter funds from operations (FFO) of $57 million, or 21 cents per share, marking a loss of $25.8 million or 15 cents per share from the same period a year ago.

$RKLBMedAI 8/10

Rocket Lab (RKLB) Won a Major Space Force Contract. Now It Has to Prove Neutron

Rocket Lab (NASDAQ:RKLB) said Aug. 4 it won a $397 million U.S. Space Force contract under the SB-AMTI program to develop, launch and operate Flatellite satellites for airborne target tracking. The work depends on Rocket Lab’s Neutron rocket, whose first flight has been delayed to late 2026 after a Stage 1 tank failure. Rocket Lab reported Q1 FY2026 revenue of $200.3 million.

$DVHighAI 9/10

DoubleVerify Shares Rally After Nielsen Agrees to $2.15 Billion Takeover

DoubleVerify (NYSE:DV) shares rose about 13.6% premarket after Nielsen Holdings agreed to buy DV in an all-cash deal valued at about $2.15 billion. DV shareholders will receive $13.60 per share, a 30% premium to the 60-day VWAP. The boards approved; closing is expected in Q1 2027. Several brokerages cut ratings to Hold/Market Perform with targets at $13.60.

$CHTRMed

Tensions flare as $34-billion Charter-Cox cable deal nears finish line

Charter Communications is nearing California PUC approval for its $34.5B purchase of Cox Enterprises, with a vote scheduled next week. Activists are urging stronger conditions on low-income broadband affordability, disaster response, and diversity and equity commitments. Charter says it will invest at least $275M in network upgrades and $30M in outreach, and the FCC previously approved the deal with DEI safeguards.

MedAI 9/10

Nielsen To Buy DoubleVerify For $2.15 Billion In Ad Measurement Deal

Nielsen agreed to buy DoubleVerify in an all-cash deal valued at about $2.15 billion, paying $13.60 per share, a 30% premium to the stock’s 60-day VWAP as of Aug. 5. The boards approved; closing is expected by Q1 2027, subject to approvals. Pro forma revenue is expected to exceed $4 billion.

$RTXMedAI 8/10

RTX wins up to $745.4 million deal for SM-3 Block IIA interceptors, extending ballistic missile interceptor production through 2031

RTX won a U.S. Department of War deal worth up to $745.4 million for SM-3 Block IIA ballistic missile interceptors, extending production through 2031. The first tranche totals $275.6 million from the U.S. defense budget and $277.6 million from Japan’s MoD. SM-3 Block IIA uses a kinetic warhead and Mk 41 launchers. It saw documented combat use in April 2024 against Iranian missiles.